Recent Comments

Comment RSS

Steroid News and Research RSS Feed - Steroid News and Research

Phase II clinical study to evaluate Nanocort commenced

17. November 2009 03:22
Galapagos NV announced today that it has started a Phase II clinical study to evaluate Nanocort's effectiveness in treating flares in multiple sclerosis (MS). Nanocort combines less frequent treatment with lower dosage and potentially more effective delivery than other MS flare treatments. [More]

Interim data from Hollis-Eden Pharmaceuticals' Apoptone Phase I/II clinical trial presented

16. November 2009 10:21
Hollis-Eden Pharmaceuticals, Inc., today reported preliminary results of its ongoing Phase I/II clinical trial with Apoptone® (HE3235) for hormone-resistant prostate cancer (also called castrate-resistant prostate cancer or CRPC). Presented at the Molecular Targets and Cancer Therapeutics Conference, which is co-sponsored by the AACR, NCI and EORTC, the poster is titled: "Results of preclinical and clinical Phase I/II open-label dose-ranging trial with HE3235, a synthetic adrenal hormone, in Castrate Resistant Prostate Cancer (CRPC)." [More]

Effects of vitamin D deficiency amplified by lower levels of sex hormone estrogen

16. November 2009 02:53
Researchers at Johns Hopkins are reporting what is believed to be the first conclusive evidence in men that the long-term ill effects of vitamin D deficiency are amplified by lower levels of the key sex hormone estrogen, but not testosterone. [More]

OncoVista Innovative Therapies' AdnaTest BreastCancer and EMT1/StemCell products evaluated in German hospitals

11. November 2009 03:59
OncoVista Innovative Therapies, Inc. reported today that two of its proprietary products, the AdnaTest™ BreastCancer and AdnaTest EMT1/StemCell, were evaluated in Germany by the Departments of Gynecology and Obstetrics and Internal Medicine (Cancer Research) at University Hospital Essen, University of Duisburg-Essen and the Department of Gynecology and Obstetrics, University Hospital of Tuebingen. [More]

Rituximab drug potentially effective for treating Graves' eye disease, shows study

7. November 2009 00:33
A small group of patients with severe Graves' eye disease experienced rapid improvement of their symptoms - and improved vision - following treatment with the drug rituximab. Inflammation around their eyes and damage to the optic nerve were significantly reduced. The same patients had not previously responded to steroids, a common treatment for Graves' eye disease. [More]

Calbiotech awarded a SBIR contract to develop analyte specific reagents for the diagnosis of Dengue virus

6. November 2009 23:52
Calbiotech, Inc. announced today that it has been awarded a Small Business Innovative Research (SBIR) Phase I contract by the U.S. Army Medical Research and Material command. Under terms of the agreement, Calbiotech will develop analyte specific reagents (ASRs) for the diagnosis of Dengue virus. [More]

Posted in: Disease/Infection News | Pharmaceutical News

Tags: , , , , , ,

Osiris Therapeutics reports financial results for the third quarter of 2009

4. November 2009 07:50
Osiris Therapeutics, Inc., the leading stem cell therapeutic company focused on developing and marketing products to treat medical conditions in the inflammatory, cardiovascular and orthopedic areas, announced today its financial results for the third quarter of 2009. [More]

Posted in: Business / Finance

Tags: , , , , , , ,

BENLYSTA meets primary endpoint in BLISS-76 trial for systemic lupus erythematosus

2. November 2009 03:32
Human Genome Sciences, Inc. and GlaxoSmithKline PLC (GSK) today announced that BENLYSTA™ (belimumab) met the primary endpoint in BLISS-76, the second of two pivotal Phase 3 trials in seropositive patients with systemic lupus erythematosus (SLE). BLISS-76 study results through 52 weeks showed that belimumab 10 mg/kg plus standard of care achieved a statistically significant improvement in patient response rate as measured by the SLE Responder Index at Week 52, compared with placebo plus standard of care. [More]

Multicenter study finds AMD patients can benefit from cataract surgery

2. November 2009 01:32
This month's Ophthalmology, the journal of the American Academy of Ophthalmology (Academy) reports on a national study that finds cataract surgery is likely to benefit patients with age-related macular degeneration (AMD) at all stages of the disease, on a clinical trial showing that the steroid triamcinolone may be effective in advanced diabetic macular edema (DME) patients when standard treatment fails, and on the public's use of two Academy-sponsored online eye health forums. [More]

Anabolic steroids may cause severe kidney dysfunction

30. October 2009 01:48
Athletes who use anabolic steroids may gain muscle mass and strength, but they can also destroy their kidney function, according to a paper being presented at the American Society of Nephrology's 42nd Annual Meeting and Scientific Exposition in San Diego, CA. [More]

Posted in: Medical Condition News | Pharmaceutical News

Tags: , , , , , ,

Positive top-line results from Phase IIb clinical trial of cariprazine announced

29. October 2009 04:46
Forest Laboratories, Inc. and Gedeon Richter Plc today announced positive top-line results from a Phase IIb clinical trial of the novel, investigational antipsychotic agent cariprazine for the treatment of acute exacerbation of schizophrenia. [More]

CTE cases are misdiagnosed as Alzheimer's disease, says CSTE researchers

29. October 2009 04:22
The Center for the Study of Traumatic Encephalopathy (CSTE) at Boston University School of Medicine (BUSM) announced today that a recently deceased member of the NFL Hall of Fame suffered from the degenerative brain disease Chronic Traumatic Encephalopathy (CTE) when he died, becoming the 10th former NFL player diagnosed with the disease. [More]

Posted in: Medical Condition News

Tags: , , , , , , , , ,

Steroid-induced osteoporosis can now be treated with Teriparatide

29. October 2009 02:10
A recent study determined glucocorticoid-induced osteoporosis (OP) is now treatable with Teriparatide, a synthetic form of the human parathyroid hormone. Researchers found patients with glucocorticoid-induced OP who were treated with teriparatide for 36 months had a greater increase in bone mineral density (BMD) and fewer new vertebral fractures than those treated with alendronate. [More]

Isotechnika Pharma reports voclosporin Phase 2/3 clinical trial results at the AAO meeting

27. October 2009 12:34
Isotechnika Pharma Inc. today announced that results of the international Phase 2/3 clinical trials studying voclosporin, conducted by its partner Lux Biosciences, were the subject of two podium presentations at the American Association of Ophthalmology (AAO) meeting and of a presentation at the satellite meeting of the American Uveitis Society (AUS) in San Francisco, October 24-27. [More]

LX211 may become the first approved oral treatment for modifying the course of uveitis

27. October 2009 05:29
An experimental drug, LX211 (LUVENIQ-; oral voclosporin), may become the first approved oral treatment capable of modifying the course of uveitis, a group of serious eye conditions inevitably associated with either severe vision loss or substantial morbidity from steroid use. [More]
News-Medical.Net provides this medical information service in accordance with these terms and conditions. Please note that medical information found on this website is designed to support, not to replace the relationship between patient and physician/doctor and the medical advice they may provide.